Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07249164

Dexmedetomidine Medication Records and Delirium After Coronary Artery Bypass Grafting

Conditions: Delirium, Cardiac Surgical Procedures, Coronary Artery Bypass Graft (CABG), Valve Surgery, Postoperative Complications

Sex: All
Ages: 18 Years – 100 Years
Healthy volunteers: No
Enrollment: 343112
Sponsor: China Medical University Hospital

Location: China Medical University Hospital Taichung Taichung City

Summary

This retrospective observational study uses de-identified electronic health records from the TriNetX Global Collaborative Network. The procedure eligibility period is 1 January 2010 through 1 July 2025. The primary analysis concerns adults with a recorded qualifying coronary artery bypass grafting (CABG) procedure. Valve-coded procedures are examined in a separately constructed and separately matched exploratory population. The populations may overlap and do not constitute independent replication cohorts. Patients are classified by the presence or absence of a dexmedetomidine medication record on the calendar day before or the day of the index procedure. This definition does not confirm administration, dose or intraday timing. The primary outcome is a qualifying delirium or disorientation code during days 1-30. Nine secondary endpoints concern mortality and selected recorded complications during days 0-30; eight are inferential and the prolonged-ventilation code endpoint is descriptive. An inpatient or observation encounter during days 1-30 is described separately and is not interpreted as readmission. Same-day records cannot establish whether an outcome preceded or followed exposure. No treatment is assigned by the investigators. Analyses use permitted aggregate outputs, without identifiable or row-level participant data. The clinical definitions were revised with knowledge of earlier analyses. CABG primary and F05-only outcomes were first rerun on 5 September 2026 and were seen before a technical amendment permitting automatic propensity-score rematching for each outcome batch and unavoidable comparative calculations accompanying descriptive patient counts. The approved eligibility, exposure and outcome windows, codes, covariates, category boundaries and eight-test multiplicity family were not changed by that technical amendment. Subsequent technical refreshes and their source versions are recorded separately. Neither the original registration nor this amendment is presented as prospective registration of the original analysis. The investigators concluded this registered analysis without publication and do not plan further amendments to this record. A separate analysis under the same ethics approval, using a different network, study period, exposure window and outcome definitions, is being reported independently and is not part of this registration.

Eligibility Criteria

Inclusion Criteria: * A qualifying CABG-coded procedure for the primary analysis, or a qualifying valve-coded procedure for the separate exploratory analysis, during 1 January 2010 through 1 July 2025. * Age at Event 18-100 at a qualifying procedure, subject to the platform's additional age-related privacy restrictions. * A procedure-date index defined by the first qualifying procedure within the clinical period after the date and age filters, with the same eligibility logic in both exposure groups within each procedure population. * Data contributed by healthcare organisations providing demographics, diagnoses, procedures, medications and laboratory domains. * Medication-record status classified using RxNorm 48937 during days -1 through 0 relative to the qualifying index procedure. Exclusion Criteria: * An ESRD or dialysis record during days -90 through -1: ICD-10-CM N18.6, Z49 or Z99.2; SNOMED CT 265764009; ICD-10-PCS 5A1D60Z or 5A1D00Z; or ICD-9-CM 39.95. * Any R41.0 or F05 record on or before day 0 in all available prior history relative to the index procedure, applied before matching in both the CABG-coded and valve-coded populations. Primary, secondary, F05-only and encounter endpoints retain this eligibility definition. Native matching is repeated within each outcome batch, and identical matched patients across batches are not established. Some eligibility records may occur after the exposure window begins on day -1, which may introduce selection or collider bias despite application before matching. The study does not require continuous preoperative observation, complete 30-day follow-up or survival to a landmark. Missing laboratory measurements do not automatically exclude a patient. The available aggregate outputs do not permit clinical adjudication of individual procedures or confirmation that surgery is first-ever or isolated.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07249164). StuddyBuddy aggregates publicly available trial information.